NEW YORK (GenomeWeb News) – The stocks of Agilent and Celera were upgraded today by two different analysts, but the market responded in very different ways with Agilent's shares surging and Celera's falling in afternoon trade.

Agilent's stock was upgraded to "outperform" from "neutral" by Credit Suisse analyst William Stein, who also upped his target price on the shares to $20 from $15. He cited the possibility of Agilent focusing more on its bio-analytical measurement business, which is not as susceptible to the economic downturn as its electronic measurement business, this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.